Primary Outcomes
Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Time: Baseline; Week 24
Secondary Outcomes
Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Time: Baseline; Week 52
Measure: Number of Participants with 20% Improvement in American College of Rheumatology (ACR20) Response Time: Week 24
Measure: Number of Participants who Experienced One or More Treatment-Emergent Adverse Event (TEAE) Time: Baseline to end of study, up to Week 63
Measure: Number of Participants who Experienced One or More Serious Adverse Event (SAE) Time: Baseline to end of study, up to Week 63
Measure: Number of Participants with Positive Anti-Drug Antibodies (ADAs) Time: Week 2; Week 55
Measure: Anti-Drug Antibodies (ADAs) Titer Levels Time: Week 2; Week 55
Measure: Number of Participants with Confirmed Neutralizing Antibodies (NAb) Time: Week 2; Week 55